A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients

Abstract

A ten day treatment with BMTO is an effective and safe strategy to combat confirmed H. pylori infection in patients.

Effectiveness and Safety of Pylera® in Patients Infected by <b><i>Helicobacter Pylori</i></b>: A Multicenter, Retrospective, Real Life Study

“…Our study has several strengths. First, the results are obtained from the largest experience in clinical practice, confirming that the use of this new quadruple therapy is very effective, reaching an eradication rate >90%, in line with other recent real life experiences [17-19]. However, our study differs significantly from those experiences.…”

“…We found that TEAEs occurred in about 16% of treated people, and that in only a minority of cases they caused discontinuation of treatment. This TEAE rate was significantly lower than the others reported by the literature, considering both pivotal studies [13, 14] as well as real life ones [16, 19], except for the study of Di Ciaula et al [18]. In our experience, this anti- H. pylori regimen shows a TEAE rate similar to that of standard triple therapy [3].…”

“…Preliminary data show that the new 10-day treatment with 3-in-1 bismuth-based quadruple therapy (Pylera®) yields optimal rates of H. pylori eradication in clinical practice, ranging from 93 to 98% [17-19]. …”

“…However, our study differs significantly from those experiences. In particular, Di Ciaula et al [18] enrolled both symptomatic and asymptomatic subjects, while the study by Gómez Rodríguez et al [19] was small, enrolling less than 60 subjects. Therefore, our large study population reached more real results, similar to those reached by pivotal studies [13, 14].…”

“…Some European experiences in using this new formulation are now available [17-19], but the small number of patients enrolled limits all of them. The aim of the present study was to assess the cure rate achieved by this 10-day regimen of the 3-in-1 pill containing bismuth, tetracycline, and metronidazole pill in a large population of H. pylori -positive patients in clinical practice.…”